Health Services Galicia (Sergas) and Gilead have agreed to work together on the FOCUS program, an initiative that aims to eliminate the spread of blood-borne viruses, such as HIV and viral hepatitis (B and C). This is a public health program that has been developed by Gilead in the United States since 2010 and has carried out more than eight million blood tests for HIV, Hepatitis C and Hepatitis B.
The FOCUS program makes it possible to systematize the detection of these infections by integrating HIV and Hepatitis C screening tests with other tests into routine clinical settings.
The implementation of this initiative is one more example of Xunta de Galicia's ongoing commitment to public health policy. In the name of Gilead, it is a clear commitment to promote collaboration with health institutions and thus contribute to achieving the public health challenges set out in this pathology.
This program is a response to recommendations from the World Health Organization about improving screening and UNAIDS, which was published in 2014 with the goal of 90% diagnosed, 90% in treatment and 90% of virus elimination. Likewise, it responded to recommendations about HCV from the Global Health Sector Strategy – GHSS, for its acronym in English – which urges the elimination of hepatitis viruses, as one of the main threats to public health in 2030.
About the Science of Gilead
Gilead Sciences Inc. is a biopharmaceutical research company that focuses on the discovery, development and commercialization of innovative medicines in unmet areas of medical needs. The company strives to change and simplify care for people with life-threatening diseases globally. Gilead is present in more than 35 countries around the world and its headquarters is located in Foster City, California.